3.9 Article

Utility of multimodality molecular profiling for pediatric patients with central nervous system tumors

期刊

NEURO-ONCOLOGY ADVANCES
卷 4, 期 1, 页码 -

出版社

OXFORD UNIV PRESS
DOI: 10.1093/noajnl/vdac031

关键词

brain tumor; next-generation sequencing; pediatric

资金

  1. Patrick Bayly Marsano Foundation and Elizabeth's Hope
  2. Englander Institute for Precision Medicine
  3. Children's Brain Tumor Project at Weill Cornell Medicine
  4. Leon Levy Research Fellowship
  5. Feil Family Brain and Mind Research Institute
  6. National Institute of General Medical Sciences of the National Institutes of Health [T32GM007739]

向作者/读者索取更多资源

This study explored the clinical utility of wide-breadth assays, including whole-exome sequencing, RNA sequencing, and methylation array profiling, as an addition to conventional diagnostic tools for pediatric CNS tumors. The results showed that RNA sequencing and methylation profiling frequently provided clinically relevant information orthogonal to conventional methods, while whole-exome sequencing primarily added value through copy number assessment. Longitudinal cohorts comparing different molecular pathology workup strategies will be necessary to further evaluate the clinical benefits of these modalities in practice.
Background As our molecular understanding of pediatric central nervous system (CNS) tumors evolves, so too do diagnostic criteria, prognostic biomarkers, and clinical management decision making algorithms. Here, we explore the clinical utility of wide-breadth assays, including whole-exome sequencing (WES), RNA sequencing (RNA-seq), and methylation array profiling as an addition to more conventional diagnostic tools for pediatric CNS tumors. Methods This study comprises an observational, prospective cohort followed at a single academic medical center over 3 years. Paired tumor and normal control specimens from 53 enrolled pediatric patients with CNS tumors underwent WES. A subset of cases also underwent RNA-seq (n = 28) and/or methylation array analysis (n = 27). Results RNA-seq identified the driver and/or targetable fusions in 7/28 cases, including potentially targetable NTRK fusions, and uncovered possible rationalized treatment options based on outlier gene expression in 23/28 cases. Methylation profiling added diagnostic confidence (8/27 cases) or diagnostic subclassification endorsed by the WHO (10/27 cases). WES detected clinically pertinent tier 1 or tier 2 variants in 36/53 patients. Of these, 16/17 SNVs/INDELs and 10/19 copy number alterations would have been detected by current in-house conventional tests including targeted sequencing panels. Conclusions Over a heterogeneous set of pediatric tumors, RNA-seq and methylation profiling frequently yielded clinically relevant information orthogonal to conventional methods while WES demonstrated clinically relevant added value primarily via copy number assessment. Longitudinal cohorts comparing targeted molecular pathology workup vs broader genomic approaches including therapeutic selection based on RNA expression data will be necessary to further evaluate the clinical benefits of these modalities in practice.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

3.9
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据